Business Wire

Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System

6.1.2026 19:07:00 EET | Business Wire | Press release

Share

CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations.

To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software.

“Together, we are building the Industrial AI operating system – redefining how the physical world is designed, built, and run - to scale AI and create real-world impact,” said Roland Busch, President and CEO of Siemens AG. “By combining NVIDIA’s leadership in accelerated computing and AI platforms with Siemens’ leading hardware, software, industrial AI and data, we’re empowering customers to develop products faster with the most comprehensive digital twins, adapt production in real time, and accelerate technologies from chips to AI factories.”

“Generative AI and accelerated computing have ignited a new industrial revolution, transforming digital twins from passive simulations into the active intelligence of the physical world,” said Jensen Huang, founder and CEO of NVIDIA. “Our partnership with Siemens fuses the world's leading industrial software with NVIDIA's full-stack AI platform to close the gap between ideas and reality — empowering industries to simulate complex systems in software, then seamlessly automate and operate them in the physical world.”

Accelerating the Entire Industrial Lifecycle
Siemens and NVIDIA will work together to build AI-accelerated industrial solutions across the full lifecycle of products and production, enabling faster innovation, continuous optimization, and more resilient, sustainable manufacturing. The companies aim to build the world’s first fully AI-driven, adaptive manufacturing sites globally, starting in 2026 with the Siemens Electronics Factory in Erlangen, Germany, as the first blueprint.

Using an “AI Brain,” – powered by software-defined automation and industrial operations software, combined with NVIDIA Omniverse libraries and NVIDIA AI infrastructure factories can continuously analyze their digital twins, test improvements virtually, and turn validated insights into operational changes on the shopfloor.

This results in faster, more reliable decision-making from design to deployment – raising productivity while reducing commissioning time and risk. The companies aim to scale these capabilities across key verticals and several customers are already evaluating some of the capabilities including Foxconn, HD Hyundai, KION Group, and PepsiCo.

With the partnership expansion, Siemens will complete GPU acceleration across its entire simulation portfolio and expand support for NVIDIA CUDA-X libraries and AI physics models, enabling customers to run larger, more accurate simulations faster. Building on that foundation, the companies will advance toward generative simulation by using NVIDIA PhysicsNeMo and open models to provide autonomous digital twins that deliver real-time engineering design and autonomous optimization.

Advancing Electronic Design Automation for Accelerated Computing
By applying industrial AI operating logic to semiconductors and AI factories, Siemens and NVIDIA will accelerate the engines of the AI revolution. Starting with semiconductor design and building on NVIDIA’s extensive use of Siemens’ tools, Siemens will integrate NVIDIA CUDA-X libraries, PhysicsNeMo and GPU acceleration across its EDA portfolio with a focus on verification, layout, and process optimization – to target 2-10x speed-ups in key workflows.

The partnership will also add AI-assisted capabilities such as layout guidance, debug support, and circuit optimization to boost engineering productivity while meeting strict manufacturability requirements. Together, these capabilities will advance AI-native engines for design, verification, manufacturability and digital-twin approaches to shorten design cycles, improve yield, and deliver more reliable outcomes.

Designing the Next Generation of AI Factories
Siemens and NVIDIA will also jointly develop a repeatable blueprint for next-generation AI factories – accelerating the industrial AI revolution and providing the high-performance foundation for their AI-accelerated industrial portfolios.

This blueprint will balance the next-generation high-density computing demands for power, cooling and automation while ensuring technologies are well positioned for both speed and efficiency - optimizing the full lifecycle, from planning and design to deployment and operations.

The combined effort bridges NVIDIA’s AI platform roadmap, AI infrastructure expertise, partner ecosystem and the accelerated power of NVIDIA Omniverse library-based simulation with Siemens’ strengths in power infrastructure, electrification, grid integration, automation, and digital twins. Together, the companies aim to accelerate deployment, increase energy efficiency, and improve resilience for industrial-scale AI infrastructure worldwide.

Optimizing Operations Through Shared Innovation
Siemens and NVIDIA aim to accelerate each others’ operations and portfolio by implementing technologies on their own systems before scaling them across industries. NVIDIA will assess Siemens offerings to streamline and optimize its own operations and offerings, and Siemens will assess its own workloads and collaborate with NVIDIA to accelerate them and integrate AI into Siemens’ customer portfolio. By accelerating one another and improving their own systems, Siemens and NVIDIA are creating concrete proof points of value and scalability for customers.

This press release is available at https://sie.ag/284PWf

Further information and more details about the partnership of Siemens and NVIDIA: https://sie.ag/7KbWbz

Further information on NVIDIA:

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, mobility, and healthcare. The company’s purpose is to create technology to transform the everyday, for everyone. By combining the real and the digital worlds, Siemens empowers customers to accelerate their digital and sustainability transformations, making factories more efficient, cities more livable, and transportation more sustainable. A leader in industrial AI, Siemens leverages its deep domain know-how to apply AI – including generative AI – to real-world applications, making AI accessible and impactful for customers across diverse industries. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a leading global medical technology provider pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably.

In fiscal 2025, which ended on September 30, 2025, the Siemens Group generated revenue of €78.9 billion and net income of €10.4 billion. As of September 30, 2025, the company employed around 318,000 people worldwide on the basis of continuing operations. Further information is available on the Internet at https://www.siemens.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260106355227/en/

Contacts

Contact for journalists
NVIDIA Corporation
Quentin Nolibois
Phone:415-741-8356; email: qnolibois@nvidia.com

Siemens AG
Simon Krause
Phone: +49 (173) 4039683; email:krause.simon@siemens.com

Charlie DiPasquale
Phone: +1 240 481-6632; email: Charlie.dipasquale@siemens.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye